CRISPR Therapeutics AG (CRSP) Invested Capital (2015 - 2026)

CRISPR Therapeutics AG has disclosed Invested Capital across 12 years of filings, most recently posting $2.4 billion for Q1 2026.

• Invested Capital for Q1 2026 came in at $2.4 billion, up 32.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 billion (up 32.0% YoY), and the FY2025 annual result was $1.9 billion, down 0.53% from the prior year.
• Invested Capital came in at $2.4 billion for Q1 2026 at CRISPR Therapeutics AG, up from $1.9 billion in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $2.4 billion in Q1 2026 to a low of $1.7 billion in Q2 2025.
• The 5-year median for Invested Capital is $1.9 billion (2025), against an average of $2.0 billion.
• Across the five-year window, Invested Capital slipped 22.24% in 2022 and jumped 32.0% in 2026, its largest moves.
• CRISPR Therapeutics AG's Invested Capital stood at $1.9 billion in 2022, then advanced by 0.39% to $1.9 billion in 2023, then increased by 2.62% to $1.9 billion in 2024, then slipped by 0.53% to $1.9 billion in 2025, then advanced by 25.64% to $2.4 billion in 2026.
• The last three Invested Capital figures came in at $2.4 billion (Q1 2026), $1.9 billion (Q4 2025), and $1.9 billion (Q3 2025), per Business Quant data.